Cipla Set For Widespread Launch Of Combo Drug For Resistant Malaria
This article was originally published in PharmAsia News
Cipla said it is awaiting approval for a widespread launch of its combination drug for treating the falciparum form of malaria considered resistant to traditional treatments.
You may also be interested in...
FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.
More external infusion pumps used in the home and continuous glucose monitors for diabetics would be reimbursed under a proposed Medicare agency rule.
Led by the Mako surgical robot, Stryker’s third-quarter sales exceeded Wall Street analysts’ expectations as it prepares to complete the $4bn acquisition of Wright Medical.